A review on PIM kinases in tumors

被引:26
作者
Arrouchi, Housna [1 ]
Lakhlili, Wiame [1 ]
Ibrahimi, Azeddine [1 ]
机构
[1] Mohammed V Univ Rabat, Rabat Med & Pharm Sch, Lab Biotechnol MedBiotech, Rabat, Morocco
关键词
Tumor; Pim-1; kinase; Small molecule inhibitors; HALF-SANDWICH COMPLEXES; SERINE/THREONINE KINASES; PROTOONCOGENE PIM-1; STRUCTURAL BASIS; CANCER-CELLS; INHIBITORS; POTENT; DISCOVERY; BREAST; LEUKEMIA;
D O I
10.6026/97320630015040
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The Proviral Integration site for Moloney murine leukemia virus (PIM) kinases is serine/threonine kinases that promote growth and survival in multiple cell types, implicated in the pathogenesis of various diseases. Over expression of Pim-1 experimentally leads to tumor formation in mice, whereas there is no observable phenotype concerning the complete knockout of the protein. When it is over expressed it may lead to cancer development by three major ways; by inhibiting apoptosis, by promoting cell proliferation and also through promoting genomic instability. Expression in normal tissues is nearly undetectable. Recent improvements in the development of novel inhibitors of PIMs have been reviewed. Significant progress in the design of PIMs inhibitors, in which it displays selectivity versus other kinases, has been achieved within the last years. However, the development of isoform-selective PIM inhibitors is still an open task. As Pim-1 possesses oncogenic functions and is over expressed in various kinds of cancer diseases, its inhibition provides a new option in cancer therapy. A PubMed literature search was performed to review the currently available data on Pim-1 expression, regulation, and targets; its implication in different types of cancer and its impact on prognosis is described. Consequently, designing new inhibitors of PIMs is now a very active area of research in academic and industrial laboratories.
引用
收藏
页码:40 / 45
页数:6
相关论文
共 69 条
  • [1] Synthesis, Kinase Inhibitory Potencies, and in Vitro Antiproliferative Evaluation of New Pim Kinase Inhibitors
    Akue-Gedu, Rufine
    Rossignol, Emilie
    Azzaro, Stephane
    Knapp, Stefan
    Filippakopoulos, Panagis
    Bullock, Alex N.
    Bain, Jenny
    Cohen, Philip
    Prudhomme, Michelle
    Anizon, Fabrice
    Moreau, Pascale
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (20) : 6369 - 6381
  • [2] Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors
    An, Ningfei
    Xiong, Ying
    LaRue, Amanda C.
    Kraft, Andrew S.
    Cen, Bo
    [J]. CANCER RESEARCH, 2015, 75 (24) : 5318 - 5328
  • [3] Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update
    Arunesh, Gubbi M.
    Shanthi, Ekambaram
    Krishna, Mudeenahally H.
    Kumar, Jegatheesan Sooriya
    Viswanadhan, Vellarkad N.
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2014, 24 (01) : 5 - 17
  • [4] Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
    Balko, Justin M.
    Giltnane, Jennifer M.
    Wang, Kai
    Schwarz, Luis J.
    Young, Christian D.
    Cook, Rebecca S.
    Owens, Phillip
    Sanders, Melinda E.
    Kuba, Maria G.
    Sanchez, Violeta
    Kurupi, Richard
    Moore, Preston D.
    Pinto, Joseph A.
    Doimi, Franco D.
    Gomez, Henry
    Horiuchi, Dai
    Goga, Andrei
    Lehmann, Brian D.
    Bauer, Joshua A.
    Pietenpol, Jennifer A.
    Ross, Jeffrey S.
    Palmer, Gary A.
    Yelensky, Roman
    Cronin, Maureen
    Miller, Vincent A.
    Stephens, Phillip J.
    Arteaga, Carlos L.
    [J]. CANCER DISCOVERY, 2014, 4 (02) : 232 - 245
  • [5] Discovery of N-substituted 7-azaindoles as PIM1 kinase inhibitors - Part I
    Barberis, Claude
    Moorcroft, Neil
    Arendt, Chris
    Levit, Mikhail
    Moreno-Mazza, Sandra
    Batchelor, Joseph
    Mechin, Ingrid
    Majid, Tahir
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (20) : 4730 - 4734
  • [6] PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer
    Braso-Maristany, Fara
    Filosto, Simone
    Catchpole, Steven
    Marlow, Rebecca
    Quist, Jelmar
    Francesch-Domenech, Erika
    Plumb, Darren A.
    Zakka, Leila
    Gazinska, Patrycja
    Liccardi, Gianmaria
    Meier, Pascal
    Gris-Oliver, Albert
    Cheang, Maggie Chon U.
    Perdrix-Rosell, Anna
    Shafat, Manar
    Noel, Elodie
    Patel, Nirmesh
    McEachern, Kristen
    Scaltriti, Maurizio
    Castel, Pau
    Noor, Farzana
    Buus, Richard
    Mathew, Sumi
    Watkins, Johnathan
    Serra, Violeta
    Marra, Pierfrancesco
    Grigoriadis, Anita
    Tutt, Andrew N.
    [J]. NATURE MEDICINE, 2016, 22 (11) : 1303 - 1313
  • [7] PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers
    Brault, Laurent
    Gasser, Christelle
    Bracher, Franz
    Huber, Kilian
    Knapp, Stefan
    Schwaller, Juerg
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (06): : 1004 - 1015
  • [8] Ruthenium half-sandwich complexes as protein kinase inhibitors:: An N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety
    Bregman, Howard
    Meggers, Eric
    [J]. ORGANIC LETTERS, 2006, 8 (24) : 5465 - 5468
  • [9] Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in Moloney murine leukemia virus (PIM-1) kinase
    Bullock, AN
    Debreczeni, JÉ
    Fedorov, OY
    Nelson, A
    Marsden, BD
    Knapp, S
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (24) : 7604 - 7614
  • [10] Structure and substrate specificity of the Pim-1 kinase
    Bullock, AN
    Debreczeni, J
    Amos, AL
    Knapp, S
    Turk, BE
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (50) : 41675 - 41682